Ocular Therapeutix (OCUL) Reports In-Line Q4 EPS

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.44 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Ferguson to acquire FloWorks for $1.6 billion in cash deal
• Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data